Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review

• Published in: International Journal of Pharmaceutics
• Main Author: Shazleen Ibrahim I.; Starlin Chellathurai M.; Mahmood S.; Hakim Azmi A.; Harun N.; Ulul Ilmie Ahmad Nazri M.; Muzamir Mahat M.; Mohamed Sofian Z.
• Format: Review
• Language: English
• Published: Elsevier B.V. 2024
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181882337&doi=10.1016%2fj.ijpharm.2023.123735&partnerID=40&md5=a6c0fe8ff883fc14b62d5c95d8a58466

Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5-year survival rate for stage IV CRC patients. Conventional treatments for advanced malignancies such as chemotherapy, often face limitations in effectively targeting cancer cells resulting in off-target distribution and significant side effects. In the quest for better strategies, researchers have explored numerous alternatives. Among these, nanoparticles (NPs) specifically liposomes have emerged as one of the most promising candidates in developing targeted delivery systems for cancer therapeutics. This review discusses the current approaches employing functionalised liposomes to overcome major biological barriers in therapeutics delivery for CRC treatment. We have also shared our perspectives on the technological development of liposomes for future clinical use and highlighted a few useful insights on the material choices for future research work in CRC. © 2023 Elsevier B.V.